Controlled Release Society Elects University of Pittsburgh’s Steven Little to Prestigious College of Fellows
The world’s leading organization for delivery science and technology has recognized University of Pittsburgh Professor and co-founder of Qrono Inc. Steven R. Little with election to its College of Fellows.
Qrono Inc. to Present at Cooley’s 2020 National Capital Call Event
Qrono will present at Cooley LLP's 1st ever online national Digital Health & Life Sciences Capital Call. 6/4 11:30am-1:30pm. This invitation-only event showcases Qrono and sixteen other life science and health companies. Qrono will present its new antigen presenting cell-specific checkpoint inhibitor program.
Steve Little wins recognition as Young Investigator of 2018
Qrono co-founder Prof. Steven Little was named Young Investigator of 2018 by Controlled Release Society. This award acknowledges his advances in long acting formulation design and development, which have been commercialized by Qrono Inc.
The Pittsburgh Business Times has selected Qrono Inc. for its first annual Innovation Award based on the company’s potential to impact the healthcare industry. This award recognizes Qrono for challenging conventional thinking with its new cancer therapies.
National Cancer Institute funds IND studies for QR206
The National Cancer Institute, part of the National Institutes of Health, has awarded Qrono Inc. a $1.5M small business innovation research contract to advance lead product candidate QR206 through Investigational New Drug studies.